About ZymoGenetics
Overview
ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. In addition to RECOTHROM, the Company is developing a diverse pipeline of proprietary product candidates that are moving into and through clinical development. These span a wide array of clinical opportunities, including autoimmune and viral diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners and out-licensing of patents from its extensive patent portfolio.
Highlights
- Track record of success. ZymoGenetics has been actively involved in the discovery and development of therapeutic protein-based products for more than 25 years. During that time, the Company has contributed to the discovery or development of six recombinant protein products currently marketed by other companies. These products have aggregate annual sales of more than $3 billion.
- Focused on therapeutic protein-based products. ZymoGenetics is engaged in the discovery and development of novel therapeutic protein-based products for the prevention or treatment of human disease. The Company has an extensive pipeline in various stages of research and development that target a broad range of diseases and conditions.
- Leading intellectual property position in potential therapeutic proteins. ZymoGenetics' early focus on therapeutic proteins has enabled the Company to build an extensive patent portfolio, with more than 300 issued or allowed United States patents. In addition, ZymoGenetics has more than 650 issued or allowed foreign patents.
To learn more, visit ZymoGenetics.com
Corporate Headquarters:
ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle, WA 98102-3702
Phone: (206) 442-6600
or (800) 775-6686
RECOTHROM is a registered trademark of ZymoGenetics, Inc.
©2010 by ZymoGenetics, Inc. All rights reserved.
